Financials
Cellex’ revenues are mainly related to the sales of SUSPENCE.
Cellex sells not only the bioreactor but a kit including SUSPENCE, sensors, pump and reservoirs. For low-volume versions of the product (<500 ml), the culture chamber is disposable, to limit the issues related to sterilization. Tutorials and assistance services are supplied in the purchase, installation, use and maintenance phases.
The technological development of SUSPENCE is currently TRL7, according the international scale. In fact, the product has been tested in an industrially relevant environment.
SUSPENCE has been developed between 2012 and 2018 through private investments by Cellex’ founders.
In 2018, Cellex obtained a € 56.003,60 funding from the European Community and Lazio Regional Government, through the Institution Lazio Innova, within the program POR/FESR 2014-2020 – Azione 1.4.1 “Sostegno alla creazione e al consolidamento di start-up innovative ad alta intensità di applicazione di conoscenza e alle iniziative di spinoff della ricerca in ambiti in linea con le Strategie di specializzazione intelligente [anche tramite la promozione delle fasi di pre-seed e seed e attraverso strumenti di venture capital]”- Asse prioritario 1 – Ricerca e Innovazione. – Bando Pre-SEED – Determinazione 27 marzo 2017, n. G03793. This grant allowed Cellex to test its technology in the case of higher fluid volumes, paving the way for tailoring SUSPENCE for the needs of Pharma industry.
In 2019, Cellex gained the SME Instrument Phase I grant (agreement n. 867199) through which a feasibility study has been carried out about the scalability of SUSPENCE to an international playground.
In 2020, a development plan for a total amount of € 429.560 has been prepared, thanks to the “Smart and Start” support by the Italian Ministry of Economic Development. Also, in 2020, Cellex has been awarded the “Seal of Excellence” by the European Community.
In the last 2 years, Cellex has increased its revenues by 5000%. The next steps require a 4-year consolidation, industrialization and scale-up plan, aimed at achieving a share of the global bioreactor market between 5% (worst case) and 20% (best case).
Cellex’s value is currently estimated 14 million euros and its IRR is 68%
Ready to start a new project?
NUMBERS
%
IMPROVEMENT IN VACCINE PRODUCTION
%
IMPROVEMENT IN CELL PRODUCTION YIELD
%
IMPROVEMENT IN CELL CLUSTER PRODUCTION
%
TURNOVER INCREASE SINCE FOUNDATION
Admin Office
(+39) 06 890 26 760
Offices
Piazzale delle Belle Arti, 2
00196 Roma (Italy)
Email
info@cellex.it